Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Celsion Corporation

Market Cap 72.5L 63.21L 58.54L 54.8L 1.03Cr 68Cr 1.03Cr 6.95Cr 2.69Cr 34Cr 2.72Cr 2.66Cr 116.91Cr P/E 2026 *
-0.58x
P/E 2027 * -0.8x
Enterprise Value 72.5L 63.21L 58.54L 54.8L 1.03Cr 68Cr 1.03Cr 6.95Cr 2.69Cr 34Cr 2.72Cr 2.66Cr 116.91Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 69 08/07/2010
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%-1.25%+63.52%+114.88% 5.52TCr
+4.60%+3.02%+58.20%+47.16% 4.58TCr
-1.44%+0.39%-12.94%-19.24% 2.3TCr
-2.69%-2.10%-3.68%+379.00% 2.08TCr
+3.22%-0.84%+27.88%-34.00% 1.63TCr
+0.58%+1.08%+16.73%-38.06% 1.54TCr
-1.01%-2.30%+27.42%+171.92% 1.3TCr
+4.95%+11.70%+123.63%+252.19% 1.24TCr
+3.07%+0.14%+29.37% - 1.24TCr
Average +1.41%+2.23%+36.68%+109.23% 2.38TCr
Weighted average by Cap. +1.63%+1.48%+40.92%+99.91%

Financials

2026 *2027 *
Net sales - -
Net income -1.64Cr -1.43Cr -1.32Cr -1.24Cr -2.33Cr -154.82Cr -2.34Cr -16Cr -6.09Cr -76Cr -6.16Cr -6.03Cr -264.6Cr -2.33Cr -2.03Cr -1.88Cr -1.76Cr -3.31Cr -220.11Cr -3.33Cr -22Cr -8.66Cr -108.34Cr -8.76Cr -8.57Cr -376.2Cr
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!